Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53

Benzinga · 2d ago
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.